Equities

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc

Actions
  • Price (EUR)45.40
  • Today's Change0.000 / 0.00%
  • Shares traded2.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments215998
Total Receivables, Net----0
Total Inventory------
Prepaid expenses2.450.792.37
Other current assets, total0.190.190.19
Total current assets2460100
Property, plant & equipment, net4.045.507.00
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.210.160.05
Total assets2866108
LIABILITIES
Accounts payable3.182.171.78
Accrued expenses127.2811
Notes payable/short-term debt000
Current portion long-term debt/capital leases163.153.86
Other current liabilities, total0.040.040.13
Total current liabilities321317
Total long term debt01616
Total debt161919
Deferred income tax------
Minority interest------
Other liabilities, total3.284.705.98
Total liabilities353339
SHAREHOLDERS EQUITY
Common stock0.000.000.01
Additional paid-in capital430425419
Retained earnings (accumulated deficit)(437)(392)(350)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00(0.13)(0.06)
Total equity(6.9)3369
Total liabilities & shareholders' equity2866108
Total common shares outstanding4.424.174.17
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.